ArticleLeukemia2020
A proposal for a new staging system for extranodal natural killer T-cell lymphoma: a multicenter study from China and Asia Lymphoma Study Group.
Abstract readLetterMulticenter Study
In one paragraph
Article in Leukemia, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed.
- Trial
- [Analysis of prognostic factors of extranodal NK/T-cell lymphoma treated with pegaspargase/L-asparaginase: a multicenter retrospective study].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2023Trial
- Prognostic value of lesion dissemination onQuantitative imaging in medicine and surgery · 2026Article
- Dynamic monitoring of circulating cell-free EBV-DNA for risk assessment in early-stage natural killer/T-cell lymphoma.Blood advances · 2026Article
- A revised staging system for natural killer/T cell lymphoma incorporating skull base invasion and nasal/non-nasal subtype distinction.Cell reports. Medicine · 2026Article
- A Masked Intruder: Extranodal Natural Killer/T-Cell Lymphoma Mimicking Preseptal Cellulitis.Mayo Clinic proceedings. Innovations, quality & outcomes · 2026Article
- The impact of chemotherapy relative dose intensity on survival in elderly patients with extranodal NK/T-cell lymphoma: A retrospective cohort study.Therapeutic advances in hematology · 2026Article
- Prognostic value of the co-stimulatory molecule OX40 expression in Extranodal Natural Killer/T-cell Lymphoma.Annals of medicine · 2025Article
- Radiotherapy alone versus combined therapy in stage I natural killer/T-cell lymphoma: impact of local invasion on treatment outcomes.Clinical and experimental medicine · 2025Article
- A novel prognostic model based on CA stage for enhanced stratification and survival prediction in patients with Natural killer/T-cell lymphoma.Annals of hematology · 2025Article
- The prognostic value of hemoglobin, albumin, lymphocyte, and platelet (HALP) score in low-risk and early-stage extranodal natural killer/T cell lymphoma.Annals of hematology · 2025Article
- The prognostic value of lactate dehydrogenase/albumin ratio in extranodal natural killer/T cell lymphoma.BMC cancer · 2025Article
- New FDG-PET/CT interpretation criteria (Huaxi criteria) for response assessment in patients with nasal-type extranodal NK/T-cell lymphoma: development and validation.Annals of hematology · 2025Article
- Incidence, Prognostic Factors, and Treatment Impact on Survival in Natural Killer/T-Cell Lymphoma: Population-Based Study in the United States.JMIR formative research · 2025Article
- Article
- Clinical Manifestations, Prognostic Factors, and Outcomes of Extranodal Natural Killer T-Cell Lymphoma: A Single-Center Experience in Thailand.Hematology reports · 2024Article
- MYC overexpression in natural killer cell lymphoma: prognostic and therapeutic implications.Haematologica · 2024Article
- Clinicopathological analysis of immunohistochemical CD47 and signal-regulatory protein-α expression in Extranodal Natural killer/T-cell lymphoma.Annals of hematology · 2024Article
- Full-spectral genome analysis of natural killer/T cell lymphoma highlights impacts of genome instability in driving its progression.Genome medicine · 2024Article
- Article
Corrections and comments
- Commented on by
Authors and funding
30 authors.
Huangming Hong *Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in Southern China, and Collaborative Innovation Center of Cancer Medicine, Guangzhou, China.
Yexiong Li *Department of Radiation Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, China.
Soon Thye Lim *Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore.
Chaoyong Liang *Department of Medical Oncology, Guangxi Medical University Cancer Hospital, Nanning, China.
He Huang *Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in Southern China, and Collaborative Innovation Center of Cancer Medicine, Guangzhou, China.
Pingyong YiDepartment of Medical Oncology, Hunan Cancer Hospital, Changsha, China.
Tao WuDepartment of Lymphoma-Oncology, Guizhou Cancer Hospital, Guiyang, Guizhou, China.
Xin DuDepartment of Hematology, Guangdong General Hospital, Guangzhou, China.
Mingzhi ZhangDepartment of Medical Oncology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Jinghua WangDepartment of Medical Oncology, Nanjing General Hospital of Nanjing Military Command, Nanjing, China.
Jun ZhuDepartment of Lymphoma-Oncology, Peking University Cancer Hospital, Beijing, China.
Ting LiuDepartment of Hematology, West China Hospital of Sichuan University, Chengdu, China.
Fanyi MengDepartment of Hematology, Nanfang Hospital of Southern Medical University, Guangzhou, China.
Gang WuDepartment of Radiation Oncology, Wuhan Union Hospital, Wuhan, China.
Ye GuoDepartment of Medical Oncology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.
Yuan ZhuDepartment of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou, China.
Weili ZhaoDepartment of Hematology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Jie JinDepartment of Hematology, the First Affiliated Hospital Zhejiang University, Hangzhou, China.
Juan LiDepartment of Hematology, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Yanming DengDepartment of Medical Oncology, the First People's Hospital of Foshan, Foshan, China.
Kangsheng GuDepartment of Medical Oncology, the First Affiliated Hospital of Anhui Medical University, Hefei, China.
Xiangyuan WuDepartment of Medical Oncology, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Xiaoyan KeDepartment of Hematology, Peking University Third Hospital, Beijing, China.
Derong XieDepartment of Medical Oncology, Sun Yat-sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.
Daren LinDepartment of Medical Oncology, Jiangmen Central Hospital, Jiangmen, China.
Zhigang PengDepartment of Medical Oncology, the First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Junxin WuDepartment of Radiation Oncology, Fujian Provincial Cancer Hospital, Fuzhou, Fujian, China.
Qing LiuDepartment of Epidemiology, Sun Yat-sen University Cancer Center, Guangzhou, China.
Won Seog KimDivision of Hematology Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Tongyu LinDepartment of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in Southern China, and Collaborative Innovation Center of Cancer Medicine, Guangzhou, China. tongyulin@hotmail.com.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
AdultAgedCombined Modality TherapyFemaleHumansLymphoma, Extranodal NK-T-CellMaleMiddle AgedNeoplasm Staging
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.